Your browser is no longer supported. Please, upgrade your browser.
Arrowhead Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.22 Insider Own0.20% Shs Outstand104.10M Perf Week1.47%
Market Cap6.91B Forward P/E- EPS next Y-0.48 Insider Trans-9.80% Shs Float100.62M Perf Month8.63%
Income-125.90M PEG- EPS next Q-0.10 Inst Own65.60% Short Float3.09% Perf Quarter-24.18%
Sales107.60M P/S64.19 EPS this Y-221.80% Inst Trans-2.05% Short Ratio3.96 Perf Half Y-3.66%
Book/sh4.20 P/B15.46 EPS next Y40.70% ROA-20.00% Target Price87.92 Perf Year41.92%
Cash/sh4.85 P/C13.38 EPS next 5Y7.33% ROE-28.00% 52W Range41.26 - 93.66 Perf YTD-15.38%
Dividend- P/FCF41.31 EPS past 5Y12.10% ROI-20.20% 52W High-30.67% Beta1.24
Dividend %- Quick Ratio2.70 Sales past 5Y196.80% Gross Margin- 52W Low57.37% ATR2.26
Employees98 Current Ratio2.70 Sales Q/Q67.50% Oper. Margin- RSI (14)50.22 Volatility3.69% 3.49%
OptionableYes Debt/Eq0.00 EPS Q/Q-115.10% Profit Margin- Rel Volume2.23 Prev Close63.66
ShortableYes LT Debt/Eq0.00 EarningsAug 05 AMC Payout- Avg Volume785.45K Price64.93
Recom2.20 SMA200.53% SMA500.29% SMA200-10.92% Volume1,753,897 Change1.99%
Aug-06-21Reiterated Chardan Capital Markets Buy $97 → $94
Jun-04-21Resumed Robert W. Baird Neutral $85
Feb-05-21Reiterated H.C. Wainwright Buy $90 → $95
Dec-21-20Downgrade Robert W. Baird Outperform → Neutral $75
Dec-16-20Initiated UBS Buy $95
Nov-19-20Initiated Citigroup Buy $90
May-13-20Initiated RBC Capital Mkts Outperform $62
May-08-20Upgrade Oppenheimer Perform → Outperform $58
Apr-15-20Upgrade Cantor Fitzgerald Neutral → Overweight $55 → $60
Mar-24-20Upgrade SVB Leerink Underperform → Mkt Perform $29
Mar-17-20Initiated Goldman Neutral $45
Jan-21-20Initiated SVB Leerink Underperform $32
Dec-13-19Initiated Oppenheimer Perform
Nov-29-19Reiterated Chardan Capital Markets Buy $45 → $81
Nov-27-19Reiterated B. Riley FBR Buy $59 → $83
Nov-25-19Upgrade Robert W. Baird Neutral → Outperform $70
Oct-24-19Downgrade Robert W. Baird Outperform → Neutral $39
Oct-22-19Reiterated Chardan Capital Markets Buy $32 → $45
Oct-03-19Initiated Robert W. Baird Outperform $39
Sep-07-18Upgrade B. Riley FBR Neutral → Buy $18 → $19
Sep-13-21 08:11AM  
Sep-01-21 07:30AM  
Aug-27-21 01:51AM  
Aug-10-21 07:12AM  
Aug-06-21 02:01AM  
Aug-05-21 04:00PM  
Jul-29-21 07:30AM  
Jul-21-21 10:06AM  
Jul-19-21 10:46AM  
Jul-14-21 07:30AM  
Jul-06-21 11:49AM  
Jul-02-21 12:22PM  
Jun-30-21 07:30AM  
Jun-26-21 06:15AM  
Jun-25-21 07:30AM  
Jun-23-21 07:30AM  
Jun-21-21 07:30AM  
Jun-03-21 07:30AM  
Jun-02-21 07:30AM  
May-18-21 09:10AM  
May-13-21 01:56AM  
May-12-21 04:00PM  
May-06-21 07:05AM  
May-05-21 02:01AM  
May-04-21 04:00PM  
May-03-21 12:53PM  
Apr-30-21 01:36PM  
Apr-28-21 11:47AM  
Apr-26-21 01:28AM  
Apr-16-21 07:30AM  
Apr-15-21 07:30AM  
Mar-09-21 01:16PM  
Mar-01-21 07:30AM  
Feb-17-21 12:39PM  
Feb-11-21 11:10PM  
Feb-09-21 10:24AM  
Feb-05-21 07:30PM  
Feb-04-21 05:31PM  
Jan-28-21 11:25AM  
Jan-25-21 07:30AM  
Jan-19-21 04:00PM  
Dec-19-20 09:18PM  
Dec-07-20 04:10PM  
Dec-02-20 08:00AM  
Nov-30-20 04:00PM  
Nov-28-20 01:23AM  
Nov-25-20 07:30AM  
Nov-23-20 09:00PM  
Nov-13-20 10:00AM  
Nov-09-20 07:30AM  
Nov-04-20 07:30AM  
Nov-02-20 04:00PM  
Oct-31-20 06:43AM  
Oct-15-20 05:00PM  
Oct-14-20 05:29PM  
Oct-10-20 08:04AM  
Oct-08-20 09:20AM  
Oct-06-20 10:46AM  
Sep-30-20 04:01PM  
Sep-24-20 04:30PM  
Sep-21-20 05:41AM  
Sep-17-20 11:28PM  
Sep-16-20 04:24PM  
Sep-10-20 10:37AM  
Sep-08-20 07:30AM  
Sep-07-20 07:01AM  
Aug-31-20 04:50AM  
Aug-28-20 07:30AM  
Aug-18-20 08:00AM  
Aug-11-20 07:30AM  
Aug-10-20 07:15AM  
Aug-05-20 04:00PM  
Jul-29-20 07:30AM  
Jul-28-20 07:08PM  
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in Phase I/II clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase I/II clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase I/II clinical trial for treating liver diseases; ARO-ENaC, which is in Phase I/II clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase Ib for the treatment of clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
OLUKOTUN ADEOYE YDirectorSep 13Sale63.765,000318,8009,000Sep 14 05:25 PM
GIVEN DOUGLAS BDirectorSep 09Sale65.245,000326,200109,868Sep 10 04:53 PM
De Backer MarianneDirectorJun 24Sale89.855,000449,25021,500Jun 25 06:59 PM
Hassard JamesChief Commercial OfficerJun 22Sale89.223,625323,422105,750Jun 24 06:44 PM
GIVEN DOUGLAS BDirectorJun 22Sale89.214,500401,445114,868Jun 24 04:47 PM
GIVEN DOUGLAS BDirectorFeb 22Sale88.731,12599,82113,875Feb 24 06:51 PM
O'Brien PatrickGeneral CounselFeb 08Option Exercise5.2290,000469,800383,375Feb 10 05:56 PM
O'Brien PatrickGeneral CounselFeb 08Sale88.4690,0007,961,240293,375Feb 10 05:56 PM
GIVEN DOUGLAS BDirectorJan 15Sale83.283,000249,84012,500Jan 19 05:58 PM
Hamilton James CSenior Vice PresidentJan 14Sale81.2910,000812,942126,250Jan 15 05:49 PM
Myszkowski Kenneth AllenChief Financial OfficerJan 12Sale81.001,441116,721444,005Jan 12 06:06 PM
Myszkowski Kenneth AllenChief Financial OfficerJan 11Sale81.0211,597939,589445,446Jan 12 06:06 PM
Hassard JamesChief Commercial OfficerJan 07Sale75.0015,6251,171,875109,375Jan 08 06:05 PM
O'Brien PatrickGeneral CounselJan 06Sale72.4125,0001,810,346293,375Jan 07 06:11 PM
Myszkowski Kenneth AllenChief Financial OfficerJan 06Sale72.4430,6252,218,477457,043Jan 07 06:08 PM
Hamilton James CSenior Vice PresidentJan 06Sale72.4819,3751,404,276136,250Jan 07 06:02 PM
Hamilton James CSenior Vice PresidentJan 05Sale72.5319,3751,405,303155,625Jan 07 06:02 PM
PERRY MICHAEL SDirectorJan 04Sale76.094,000304,36090,000Jan 05 06:14 PM
GIVEN DOUGLAS BDirectorJan 04Sale76.084,000304,320119,368Jan 05 06:11 PM
Waddill William D.DirectorJan 04Sale76.083,750285,30030,250Jan 05 06:01 PM
Anzalone Christopher RichardChief Executive OfficerDec 18Option Exercise5.7340,510232,0062,545,747Dec 22 05:55 PM
GIVEN DOUGLAS BDirectorDec 17Sale79.5950039,79515,000Dec 18 06:26 PM
GIVEN DOUGLAS BDirectorDec 17Sale79.309,075719,648114,738Dec 18 06:26 PM
Waddill William D.DirectorDec 10Sale71.263,000213,78025,000Dec 11 06:16 PM
Anzalone Christopher RichardChief Executive OfficerDec 09Option Exercise2.0138,67677,7392,543,913Dec 10 07:07 PM
Anzalone Christopher RichardChief Executive OfficerDec 09Sale69.0638,6762,670,8052,505,237Dec 10 07:07 PM
Anzalone Christopher RichardChief Executive OfficerDec 08Option Exercise2.0116,32432,8112,521,561Dec 10 07:07 PM
Anzalone Christopher RichardChief Executive OfficerDec 08Sale67.9716,3241,109,5422,505,237Dec 10 07:07 PM
Bradshaw CurtChief Scientific OfficerNov 20Sale68.7315,6251,073,9060Nov 23 05:58 PM
Bradshaw CurtChief Scientific OfficerNov 19Sale69.3915,6251,084,21915,625Nov 23 05:58 PM
San Martin JavierChief Medical OfficerNov 19Sale69.3919,5001,353,105130,500Nov 20 06:03 PM
Myszkowski Kenneth AllenChief Financial OfficerNov 09Option Exercise14.5443,505632,563471,173Nov 12 05:49 PM
Myszkowski Kenneth AllenChief Financial OfficerNov 09Sale69.3743,5053,018,071427,668Nov 12 05:49 PM
Anzalone Christopher RichardChief Executive OfficerOct 23Sale58.21100,0005,821,0322,505,237Oct 23 07:35 PM
Myszkowski Kenneth AllenChief Financial OfficerOct 20Option Exercise6.1529,166179,371456,834Oct 22 06:02 PM
Myszkowski Kenneth AllenChief Financial OfficerOct 20Sale54.0429,1661,576,131427,668Oct 22 06:02 PM
Ferrari MauroDirectorOct 09Sale48.0010,000480,00030,971Oct 13 06:01 PM
De Backer MarianneDirectorOct 08Buy50.471,00050,46517,500Oct 26 06:02 PM